29 April 2024
Efferon LPS receives CE mark under EU MDR

Efferon LPS receives CE mark approval in the European Union as a class 2b medical device under MDR requirements.
Efferon LPS is a single-use adsorbent-filled cartridge for extracorporeal blood purification. Patients’s blood is perfused through the adsorbent and is returned into bloodstream. Tailored surface and structure of adsorbent beads bind bacterial endotoxins and excessive inflammatory mediators (such as cytokines) and remove then from the circulation.
Multicenter randomised clinical study [Shock. 2023 Jun 1;59(6):846-854] validated safety and efficacy of Efferon LPS in patients with septic shock. This treatment improved their vital functions, reduced duration of multiple organ deficiency and increased survival rate.
We congratulate physicians, patients and their families who are gaining long awaited access to an innovative extracorporeal treatment of sepsis, septic shock and multiple organ failure syndrome.
Sepsis is a deadly foe and now we will fight it together.
More news
- Efferon®NEO Receives CE MDR Mark22 April 2026
- Efferon at ISICEM10 April 2026
- Efferon first distributors meeting08 April 2026
- Efferon is now available in Poland11 March 2026
- Efferon®LPS is available in Costa Rica26 February 2026
- Efferon®LPS is now approved in Thailand18 February 2026
- Efferon LPS® incorporated into clinical guidelines of the German Society of Nephrology for therapeutic apheresis10 December 2025
- We’ll see each other in Greece25 November 2025
- Efferon therapies are now available in Armenia!05 November 2025
- Clinical data confirmed the effectiveness of Efferon NEO in children with sepsis30 October 2025
- Efferon LPS has been approved in the Kingdom of Saudi Arabia.18 October 2025
- Extracorporeal removal of antibiotic drugs during Efferon LPS hemoadsorption is predictable and manageable09 October 2025
- Efferon at the 6th Asia Pacific AKI CRRT Congress in Bangkok05 October 2025
- Win a New iPad! Join the Efferon LPS Photo Challenge on LinkedIn12 September 2025
- Efferon LPS hemoadsorption device has been granted regulatory approval in the United Kingdom and Croatia.23 July 2025
- Efferon LPS Now Available in Italy01 July 2025
- Applying Vicenza’s Lessons28 June 2025
- Efferon Expands Its Global Presence23 June 2025
- Efferon expands to new markets with Bertossi partnership06 June 2025
- Efferon LPS becomes available in Romania.25 May 2025
- New distribution agreements in European countries22 July 2024
- Results of LASSO mRCT are published in Shock20 April 2023
- Efferon at LIVES 2022 in Paris03 November 2022
- Efferon has participated in MEDICA30 November 2021
- LASSO multicenter randomized trial launched29 April 2021